Vaccines
VACCINES
CELL THERAPIES
GENE THERAPIES
BIOLOGICALS
COVAXIN™
Unique to COVAXIN™ (BBV152) is its novel, Algel-IMDG (TLR 7/8) adjuvant, which together with the inactivated virus is designed to elicit an immune response against multiple antigens (S1, N and RBD) and generate memory T cell responses against several epitopes. IMDG is a novel immunomodulator developed in collaboration with the National Institutes of Health. It can be stored at 2-8 °C for up to two years, and is stable for six months at room temperature (25°C).
COVAXIN™ (BBV152) was co-developed with Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
COVAXIN™ (BBV152) is a two-dose vaccine given at Days 0 and 28. COVAXIN™ (BBV152) demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%. Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events. It is under clinical investigation in the U.S. for use in adults 18+ based on a Phase 3 clinical trial conducted in India and whose results were published in The Lancet.
An additional study has shown how the candidate vaccine generates neutralizing antibodies against the Omicron and Delta variants.
LEARN MORE ABOUT OUR VACCINE CANDIDATE
COVAXIN™ Publications
- Preclinical Product Development
- Animal Challenge Studies – Hamsters
- Animal Challenge Studies – Rhesus Macaques
- Human Clinical Trials – Phase I
- Human Clinical Trials – Phase II
- Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2
- COVAXIN effectively neutralizes B.1.617 variant of SARS-CoV-2
- Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
- Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
- Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
- Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
OCU500
OCU500 is unique from any other COVID-19 vaccine (including AAV, mRNA and Protein subunit) as it incorporates two mutations into the spike protein that enhances antibody response.
Other features include:
- Non-invasive
- Needle-free administration
- Potential for increased compliance
- Scalable manufacturing
- Stored and shipped at standard refrigerated conditions
- Potential to develop multi-strain and variant specific versions
STAY CONNECTED
Contact us for more information
Copyright @ 2021.